'Thor­ough­ly f*****d' for cy­ber­at­tacks?; Bad week for drug de­vel­op­ers; The next big I/O break­through?; Bio­gen does a deal; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

If you no­ticed the ex­tra bulky Phar­ma sec­tion this week, that’s be­cause we’ve of­fi­cial­ly launched End­pointsPhar­ma — our dai­ly email re­port on all things phar­ma strat­e­gy, mar­ket­ing and com­mer­cial­iza­tion. If you like it, please do spread the word.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.